KRAS and non-small cell lung carcinoma: Predictive and prognostic biomarkers including EGFR mutations, ALK fusions, ROS1 fusions, MET‐14 skipping, RET rearrangement, and KRAS oncogene had been tested by next generation sequencing or amplification refractory mutation system PCR in 74 patients (including all the nonsquamous NSCLC).